Frederick Howard, MD, explored the evolving intersection of artificial intelligence (AI), computational pathology, and precision breast oncology.
|Articles|November 18, 2009
To Mammogram or not to Mammogram, and when?
News summary of the discussion about when routine mammography screening for breast cancer should begin
Advertisement
The US Preventive Services Task Force issued a report recommending “
Despite this recommendation the American Cancer Society is not changing its guideline and "continues to recommend annual screening using mammography and clinical breast examination for all women beginning at age 40". The full text of the response can be found
Related Clinical Links
Full text of the news recommendation (USPSTF website)American Cancer Society response (Cancer.org)National Guidelines Clearinghouse on Mammography (Guidelines.gov)Clinical Journal Scan (Searchmedica.com)
Clinical News
Softer Mammography Screening and Breast Exam Guidelines Draw Mixed Reaction (OncologyStat.com - registration required)USPSTF: Biennial mammography should begin at age 50 (HemOncToday.com)Panel Puts Off Mammography until Age 50 (MedPageToday.com)
What Your Patients are Reading
Screening Policy Won't Change National Officials Say (NY Times)Our Bodies, Our Breast Exams (NY Times Health Blog)Insurance Will Pay for Breast Exams (USA Today)
Advertisement
Related to this article
“Vitamin C is a powerful epigenetic drug, which is not generally realized,” said Peter A. Jones, PhD, DSc (hon).
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal cancer.
Investigators will share detailed findings from the phase 1a/b EMBOLD PanTumour-101 study at the European Society for Medical Oncology Congress 2026.
The anti–IL-1α antibody vilamakitug added to trifluridine/tipiracil met its prespecified 12-month overall survival threshold in refractory metastatic colorectal cancer.
Long-term QUILT-3.032 data showed a 71% CR rate, with a median duration of 26.6 months with nogapendekin alfa inbakicept/BCG in BCG-unresponsive NMIBC.
The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk non–muscle invasive bladder cancer.
Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Dostarlimab in Previously Untreated Locally Advanced Rectal Cancer
2
Ris-Rez Produces Anti-Tumor Activity in Extensive-Stage SCLC
3
FDA Accepts NDA for UGN-103 in Recurrent Low-Grade Intermediate-Risk NMIBC
4
Sequencing CAR T-Cell Therapy and Bispecifics to Preserve T-Cell Fitness
5